

## 1.0.7 DOC EIA

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## NICE guidelines

### Equality impact assessment

#### **Familial breast cancer**

The impact on equality has been assessed during guidance development according to the principles of the NICE equality policy.

#### **4.0 Final guideline (to be completed by the Developer before GE consideration of final guideline)**

4.1 Have any additional potential equality issues been raised during the consultation, and, if so, how has the Committee addressed them?

No.

4.2 If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access services compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

4.3 If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

## 1.0.7 DOC EIA

4.4 If the recommendations have changed after consultation, are there any recommendations or explanations that the Committee could make to remove or alleviate barriers to, or difficulties with, access to services identified in questions 4.2, 4.3 and 4.4, or otherwise fulfil NICE's obligations to advance equality?

The committee wished to highlight the use of a decision aid to be developed alongside this update would improve issues around access of information on chemopreventive agents, allowing women to make informed preferences in a shared decision making environment.

4.5 Have the Committee's considerations of equality issues been described in the final guideline document, and, if so, where?

Yes - these are contained in the 'other considerations' section of the Linking Evidence To Recommendations table in the guideline. Relevant subgroups have also been specified in the review protocol.

Updated by Developer: Nicole Elliott, Associate Director – Clinical Guidelines Update Team

Date: 3 February 2017

Approved by NICE quality assurance lead Sharon Summers-Ma, Associate Director - Commissioning

Date: 16 February 2017